Tissue Regenix Group PLC Issue of Equity and Total Voting Rights (5685B)
07 June 2019 - 11:55PM
UK Regulatory
TIDMTRX
RNS Number : 5685B
Tissue Regenix Group PLC
07 June 2019
Tissue Regenix Group plc
Issue of Equity and Total Voting Rights
Leeds, 07 June 2019 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Company"), the regenerative medical
devices company, announces that it has today issued and allotted
240,499 ordinary shares of 0.5p each in the Company, following an
exercise of options which were granted in respect of the 2015 and
2018 DAB awards.
The 240,499 new ordinary shares will rank pari passu with the
existing ordinary shares and application will shortly be made for
these new ordinary shares to be admitted to trading on AIM. It is
expected that Admission will occur at 8:00a.m. on 13 June 2019.
Total Voting Rights
Following the issue of the 240,499 new ordinary shares, the
Company will have a total of 1,171,971,322 ordinary shares of 0.5p
each in issue. The above figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson Head of Communications 07920272 441
--------------------------------------------- ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Victoria Foster Mitchell
/ Mary Whittow
============================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFRMJTMBIMBJL
(END) Dow Jones Newswires
June 07, 2019 09:55 ET (13:55 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024